Plain-English translation of NCT06948448 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a new medication, given alongside two well-established cancer treatments (Opdivo and standard chemotherapy with ) for advanced colorectal cancer. Researchers want to know if adding this medication helps patients live longer and controls their cancer better than the standard treatment alone. You would be randomly assigned to receive one of two different doses of the medication combined with standard care, or to receive standard care by itself.
Some patients with advanced colorectal cancer do not respond well enough to current standard treatments. This trial is testing whether this medication can boost the immune system's ability to fight the cancer and improve outcomes for people whose tumors have a specific marker (PD-L1 positive).
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly during 28-day treatment cycles to receive the medication and standard chemotherapy infusions, along with . Treatment would continue as long as your cancer responds and you tolerate the medications well, unless your doctor decides to stop for safety reasons or your cancer progresses. The study team would monitor you closely with blood tests, scans, and check-ins to watch for side effects and how well the treatment is working.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States